1 / 34

Comprehensive Overview of Basal Cell Carcinoma: Risks, Therapies, and Innovations

This document explores the incidence and risk factors associated with Basal Cell Carcinoma (BCC), detailing standard therapies such as Mohs Micrographic Surgery, photodynamic therapy, and emerging treatments targeting aberrant Hedgehog signaling. It covers key demographics, prognosis, and the role of combination therapies while discussing recent clinical trials and their findings. Special attention is given to the management of Basal Cell Nevus Syndrome (BCNS) and innovations in treatment methodologies that aid in combating resistance mechanisms.

ursula-melton
Télécharger la présentation

Comprehensive Overview of Basal Cell Carcinoma: Risks, Therapies, and Innovations

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Activity Goals

  2. Incidence of Basal Cell Carcinoma (BCC)

  3. Standard Therapies: Non-Melanoma Skin Cancer (NMSC)

  4. Risk Factors

  5. Risk Factors (cont)

  6. Prognosis

  7. Demographics

  8. Mohs Micrographic Surgery (MMS)a

  9. The MMS Procedure Description and Illustration

  10. Therapies for BCC

  11. Combined Topical Field Therapies

  12. Photodynamic Therapy (PDT) Procedure

  13. Topical d - ALA

  14. Role of PDT in Management of Basal Cell Nevus Syndrome (BCNS)

  15. BCNS Clinical Criteria

  16. Investigator-Initiated, Randomized, Double-Blinded Trial for 18 months

  17. 2 vs 29 New BCCs Per Year

  18. Mechanism of Aberrant Hedgehog Signaling

  19. Aberrant Hedgehog Signaling

  20. Response in Patient With Metastatic Disease

  21. Phase 1 Study of GDC-0449

  22. ERIVANCE Phase 2 for BCC

  23. Mechanisms of Acquired Resistance

  24. Decrease in Tumor Size by IRF in the Metastatic Cohort

  25. Comparison of Hedgehog Inhibitors

  26. IPI-926 Phase 1 Study

  27. Best Curative Therapy

  28. MMS: Disadvantages

  29. Combination Therapies

  30. Radiotherapy

  31. Challenges With Anti-SMO

  32. Conclusions

More Related